Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

Expression of oestrogen receptor β isoforms is regulated by transcriptional and post-transcriptional mechanisms

(2010) Laura Smith et al.   BIOCHEMICAL JOURNAL

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

(2009) L J Coleman et al.   BRITISH JOURNAL OF CANCER

Differential regulation of oestrogen receptor β isoforms by 5′ untranslated regions in cancer

(2009) Laura Smith et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

(2008) B. Shor et al.   CANCER RESEARCH

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro

(2008) Silvia Darb-Esfahani et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET